WCM
PTGX icon

Wedge Capital Management’s Protagonist Therapeutics PTGX Stock Holding History

Wedge Capital Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-135,594
Closed -$1.7M – 627
2019
Q1 		$1.7M Sell
135,594
-52,257
-28% -$461K 0.02% 303
2018
Q4 		$1.26M Hold
187,851
– – 0.02% 306
2018
Q3 		$1.93M Buy
+187,851
New +$1.62M 0.02% 282

Other funds holding PTGX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return

Wedge Capital Management's PTGX Position: Q2 2019 in Review

Wedge Capital Management sold out of Protagonist Therapeutics (PTGX) in Q2 2019, closing a stake of 135,594 shares — an estimated $1.7M sold.

Wedge Capital Management first reported a position in PTGX in Q3 2018 and held it in 3 quarters. The position peaked at $1.93M in Q3 2018. 66 funds tracked by Wall St. Rank hold PTGX as of Q2 2019.

  • Wedge Capital Management reported no remaining Protagonist Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Wedge Capital Management sold 135,594 Protagonist Therapeutics shares in Q2 2019, an estimated $1.7M.
  • Wedge Capital Management first reported a position in Protagonist Therapeutics in Q3 2018 and held it in 3 quarters.
  • Wedge Capital Management's Protagonist Therapeutics position peaked at $1.93M in Q3 2018.
  • 66 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2019.

Based on Wedge Capital Management's 13F filing for Q2 2019, filed 1 Aug 2019.